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Abstract
Background: Lymphogranuloma venereum (LGV) is an important re-emerging sexually transmitted infection which
is reported to affect particularly HIV-positive men who have sex with men (MSM). The aim of this study is to
quantify the association between LGV and HIV in the context of the current emergence of LGV.
Methods: A systematic review was performed on the emergence of LGV among MSM since 2000. We report the
prevalence of HIV infection from descriptive studies of MSM with LGV, and conduct a meta-analysis to produce a
summary estimate of the association between LGV and HIV from case-control studies where cases were MSM with
LGV and controls were MSM with rectal chlamydia caused by non-LGV serovars.
Results: The prevalence of HIV among LGV cases ranges from 67% to 100% in 13 descriptive studies. There is a
significant association between HIV and LGV (odds ratio 8.19, 95% CI 4.68-14.33).
Conclusions: HIV-positive MSM are disproportionately affected by LGV highlighting the importance of prevention
efforts to be targeted to this group. Further research is needed to determine whether the association is due to
biological or behavioural factors.
Background
Lymphogranuloma venereum (LGV) is a sexually trans-
mitted infection (STI) which largely disappeared from
the Western world after the introduction of antibiotics.
LGV is caused by the species Chlamydia trachomatis
(CT) which produces infection in humans and includes
three biovars [1]; serovars A-C cause trachoma, an eye
infection that mainly spreads via child-to-child transmis-
sion and is the leading cause of preventable blindness,
while the second biovar (serovars D-K, and occasionally
also B [2]) is transmitted sexually [3]. Serovars A-K have
a limited host-cell range, they infect mainly squamoco-
lumnar epithelial cells and are incapable of infecting
deeper tissues. The third biovar, LGV, is formed by ser-
ovars L1, L2 and L3 and it causes a more invasive dis-
ease due to its ability to infect macrophages and
consequently it can spread to lymphatic tissue at the
site of infection leading to a systemic disease [4]. LGV is
classified as a genital ulcer disease (GUD) without clear
tissue tropism for mucosa contrary to non-LGV chlamy-
dia, and it has been considered endemic in the tropics
although LGV epidemiology in these areas has not been
systematically described. In 2003 a cluster of LGV cases
was reported in Rotterdam, the Netherlands [5] and, fol-
lowing an international alert, case reports were pub-
lished of similar outbreaks in large European cities
[6-10]. Reports of LGV from the United States [11],
Canada [12] and Australia [13] followed.
The clinical features of LGV have historically been
divided into three stages: the primary stage involves the
site of inoculation where a small papule, ulcer, herpeti-
form lesion or nonspecific urethritis appears after incu-
bation period of 3-30 days [4]. During the secondary
stage, which emerges after 10-30 days or even months
later, local lymph nodes draining the site of primary
infection enlarge and necrotic areas develop following
an inflammatory process which results in chronic
oedema and formation of ulcers and sclerosing fibrosis.
Without adequate treatment a tertiary phase with
chronic inflammatory response will follow. This is
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characterized by genital ulcers, fistulas, rectal strictures
and genital elephantiasis. The scarring and formation of
fibrotic tissue often requires surgical repair [4]. The
classical manifestation in men is characterised by ingu-
inal lymphadenopathy. During the recent emergence of
LGV, the clinical manifestation has been different.
Acute ulcerative proctitis or proctocolitis is often seen
as the primary manifestation [4,14] (approximately 96%
of the cases in the United Kingdom [15]) while inguinal
lymphadenopathy alone has been observed in only a few
cases [16]. Rectal discharge, pain, bleeding [14] and sys-
temic symptoms such as malaise [17] and high white
blood cell count (>10/high power field) in gram stained
rectal smears [18] have been reported as indicators of
LGV. It is not clear why inguinal symptoms, indicating
urethral acquisition of LGV, have been so rare and it
has been suggested that different modes of transmission,
such as sexual practices of fisting and use of sex toys
and other fomites, are contributing to the spread of
LGV. Traumatic practices to the mucosa have been pre-
viously associated with the acquisition of other rare
STIs such as sexually acquired hepatitis C virus [19].
In response to the outbreak surveillance systems were
established in several affected countries. These have pro-
duced a consistent picture of cases among men who
have sex with men (MSM), many of whom are co-
infected with HIV (for example 74% co-infection rates
in the UK [20] and over 70% reported in other Eur-
opean countries [21]). On average, affected patients have
also been older (mean age above 35 [21]) than MSM
presenting to STI clinics for other reasons, and with a
high rate of concurrent STIs and hepatitis C (14% of
cases in the UK [20]). In 2009 a case-finding study in
genitourinary medicine (GUM) clinics in London found
a prevalence estimate of LGV among MSM to be 1.2%
(36 out of 3076 men) [22] while another case-finding
exercise conducted in four GUM clinics in London and
Brighton found LGV positivity among rectal samples
from MSM to be 0.9% (61 of 6778 rectal samples tested
for LGV) [23].
As LGV seems to be circulating mainly among HIV-
positive MSM it is important to consider the effect
these STIs have on each other [24]. STIs may contribute
to transmission of HIV and concurrent HIV infection
may alter the epidemiology of an STI: both STI and
HIV can become more infectious in a co-infected indivi-
dual. HIV may also increase the susceptibility of an
HIV-positive individual to other STIs and HIV may be
transmitted more easily in discordant couple if the HIV-
negative partner has a concurrent STI [25]. In meta-ana-
lysis by Rottingen et al. (2001) [25] both GUD and CT
were found to increase susceptibility to HIV-infection in
heterosexual transmission and it would seem plausible
that LGV may increase HIV transmission also in
homosexual partnerships. The aim of this study is to
quantify the association between HIV infection and
LGV among MSM in the context of the current emer-
gence of LGV.
Methods
Search strategy
A systematic review was conducted using PubMed of
the National Center for Biotechnology Information
(NCBI), MEDLINE of the National Library of Medicine
(NLM) and Web of Science (the latter two via ISI Web
of Knowledge platform). The search was restricted for
the years 2000-2009. The searches were performed on
17 June 2009 using the search words “Lymphogranu-
loma venereum” (MeSH, and topic search) and the acro-
nym LGV with Boolean search looking for any of the
words. No restrictions were selected on the type of stu-
dies, or publication language. An additional search was
done in Eurosurveillance [26] on 18 June 2009 using the
advanced search and selecting “Lymphogranuloma
venereum - LGV” from the subject list. The article
search focused on covering all scientific publications of
LGV after 2000, as case-finding and reporting of the
emergence of LGV has started after 2003. Novel diag-
nostic methods have been developed recently [27] and
this has enhanced the reliability of LGV diagnosis.
The grey literature was searched online using the web-
sites of national public health agencies and professional
organisations including the Health Protection Agency of
England and Wales, the British Association for Sexual
Health and HIV, the Public Health Agency of Canada
and the Centres for Disease Prevention and Control of
the United States. Reference lists of LGV publications
were utilised to identify relevant literature and they
were also reviewed for completeness of already found
publications. No attempt was made to identify unpub-
lished studies. Ethical approval was not sought, since the
study relied on published data only.
Study selection
The study selection was done in two stages: during the
first phase all publications involving a component of
LGV epidemiology or management of LGV were
included apart from publications focusing on the mole-
cular biology of LGV or CT which were excluded. The
study selection at this point was done based on abstract
or the full publication if abstract did not give sufficient
information. At the second phase complete publications
were reviewed and their suitability in respect to the
research objective was assessed. Studies were included if
they met the following criteria: the main outcome was
LGV and the study population was composed of MSM
with data available for the level of HIV co-infection
among study subjects. The selection of papers was
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restricted to MSM as they have been most affected by
LGV in developed countries, and because the clinical
manifestation of LGV is different among homosexuals
than heterosexuals. Case-series and conference abstracts
were excluded at the second stage of the review.
Data extraction
From the descriptive studies that met all the inclusion
criteria, the following variables were obtained: first
author, year of publication, purpose and type of the
study, study period, sample size, number of confirmed
LGV cases (confirmation of LGV status requires detec-
tion of L1-L3 serovars from a chlamydia positive sam-
ple), age as reported in the paper, number of HIV
positive LGV cases as well as number of cases with
negative or unknown HIV status. Additionally from
case-control studies information on the effect sizes and
their confidence intervals and two by two table of the
distribution of HIV serostatus was retrieved. When sev-
eral publications reported data from the same setting,
the latest or most complete report was used. The eligi-
ble publications were in English and Swedish as the first
author is fluent in both languages.
Analytic methods
To estimate the prevalence of HIV among LGV cases,
raw pooled prevalence estimates were calculated based
on the numbers of HIV-positive and negative individuals
given in the publications. A summary estimate was con-
structed and heterogeneity of the estimates explored
using meta-analysis (using inverse-variance and derSi-
monian and Laird method [28]). To calculate variance
estimates, studies were excluded if the number of
expected cases was less than 5 in order to avoid skewed
summary estimates. In order to make the distribution
nearer to normal meta-analysis was run using logits (log
of the odds) of the prevalence estimates and final results
transformed back to prevalence [29].
To analyse LGV-HIV association in case-control stu-
dies, a meta-analysis was performed using Mantel-
Haenszel fixed-effect method as presented by Petitti
(2000) [30]. For tests of heterogeneity chi-square test
was used and also random-effect method (derSimonian-
Laird method) which yields close to identical results to
fixed-effect method in the absence of heterogeneity. Sta-
tistical analyses were done using STATA10. Reporting
followed the guidance of PRISMA statement (preferred
reporting items for systematic reviews and meta-ana-
lyses) [31].
Results
Details of included and excluded articles
The search produced the following results: PubMed 270,
Medline 273 and Web of Science 264. Many citations
were common to all three search engines and after
removal of duplicates there was a total of 368 original
publications for the years 2000 to 2009. Eurosurveillance
had 21 publications under the subject heading Lympho-
granuloma venereum out of which 3 were identified
through Eurosurveillance search only[5,8,10]. Searching
the grey literature gave 4 additional LGV-related results
[32-35] and a search of the reference lists gave six more
publications [36-41] that fulfilled the primary inclusion
criteria.
During the first stage of the review 140 publications
were excluded (Figure 1). Full copies of 241 articles
were reviewed in the second stage of the review. The
systematic review identified 23 potentially relevant arti-
cles from which data extraction was performed and
after excluding 6 publications with overlapping study
period [15,17,42-45] 17 publications remained that ful-
filled the inclusion criteria
Estimating level of HIV co-infection among LGV-cases
The review identified 13 cross-sectional or descriptive
studies that provided information on the prevalence of
HIV among LGV cases. The majority were surveillance
reports of LGV cases, and characteristics are presented
in Additional file 1, Table S1. A total of 1145 confirmed
LGV cases were reported by the studies, of which 985
had epidemiological data (86.3% of cases). Among the
confirmed cases there was a high level of HIV co-infec-
tion, ranging from 67% to 100% across the reports. The
raw pooled prevalence estimate was 77.9% (95% CI 75.0-
80.8%) among cases with known HIV status. However,
there was a significant amount of missing data on HIV
status, with 19.8% of cases having unknown status. To
statistically explore heterogeneity, a meta-analysis for
the prevalence estimates was performed using the
known HIV statuses from the publications. This was
done for five studies with expected number of cases of
five or more [20,46-49] (the eligible publications are
highlighted in table S1). A fixed-effect model gave a
summary estimate of 74.5% and random-effect model
78.2% (raw pooled estimate of the included five studies
76.3%). The test for heterogeneity among these studies
was statistically significant (p-value < 0.001) and thus a
summary estimate was deemed an inappropriate
approach and should be used for illustrative purposes
only due to the underlying differences between studies.
Estimating the association between LGV and HIV
Four case-control studies were indentified that estimated
the association between LGV and HIV (Additional file 1,
Table S2). In these studies all the cases have LGV proc-
titis and included a control group with non-LGV CT
(some studies had more than one control group). A
summary OR for the HIV-positives was calculated using
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HIV-seronegative patients as a reference group, and the
resulting forest plot is presented in Figure 2. The sum-
mary estimate demonstrates that MSM with LGV are
eight times more likely to have HIV (OR 8.19, 95% CI
4.68-14.33, p-value < 0.001) compared to MSM with
non-LGV CT. The statistical test for heterogeneity did
not show a significant difference between the study
groups (p-value 0.519). Study by van der Bij has the lar-
gest weight as it has over twice as many cases and con-
trols compared to other studies. Due to the small
Excluded  n = 140 
 
Excluded based on the abstract available  
n = 135 
 
Unable to obtain further information needed 
to make assessment n = 5 
Full copies retrieved and 
assessed for eligibility 
n = 241 
Searching the grey 
literature n = 4 
 
Eurosurveillance n = 3 
 
Studies identified 
through reference lists  
n = 6 
Excluded n = 218: 
 
Conference abstracts of case-control and 
cross-sectional studies n = 10 
 
Studies of LGV, HIV co-infection was not 
reported n = 4 
 
Cross-sectional studies of MSM, no LGV 
found n = 6 
 
Cross-sectional studies of LGV and other 
STIs in the whole population n = 21 
 
Policy and behavioural surveys n = 5 
 
Case reports and series n = 62 
 
Guidelines, diagnostics and genetics of LGV 
n = 25 
 
LGV reviews, reports, news, editorials, 
letters or commentaries n = 62 
 
Other n = 23 
Publications that met the 
inclusion criteria 
n = 17 
Publications found through  
PubMed, MEDLINE and  
Web of Science (2000-2009) 
n = 368 
Potentially relevant articles 
n = 23 
Excluded n = 6 
Overlap with another study that was included 
Figure 1 Flow chart for study selection and process.
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number of people with an unknown HIV-serostatus
(only van der Bij had a large number of participants
with unknown status), the association between that and
LGV was not explored.
As a random-effect model produced very similar
results to a fixed-effect model, further statistical tests for
heterogeneity were not conducted. Sources of heteroge-
neity were explored by looking into potential differences
in the study design. There seems to have been few
methodological differences between the studies: all the
study participants were recruited on STI clinics based
on their sexual risk-behaviour or symptoms reported.
All the LGV cases were confirmed using either real-time
PCR of RFLP-PCR as were non-LGV CT controls. It is
unlikely that there are significant differences between
the study populations as three of the studies were con-
ducted in the Netherlands (two in Amsterdam and one
in Rotterdam) and one study in London, UK. Therefore
it seems that no large methodological, clinical or geo-
graphic sources of heterogeneity can be detected
between the studies.
Discussion
We found consistent evidence of a strong association
between HIV and LGV across the literature. In thirteen
descriptive studies at least two-thirds of MSM with
LGV were co-infected with HIV. In a meta-analysis,
MSM with LGV were over eight times more likely to
have HIV (OR 8.19, 95% CI 4.68-14.33) than those who
had non-LGV chlamydia infection. This association is
stronger than for other sexually transmitted infections
which have also re-emerged in MSM over the past dec-
ade [50]. As the descriptive studies presented results
mainly in aggregate form, it was not possible to further
investigate the effect of LGV genotype or rectal and
non-rectal infection on the association between HIV
and LGV. However, in the majority of studies rectal
symptoms and proctitis were the dominant manifesta-
tion of LGV, as shown by results from the three largest
studies: in the UK 90% of confirmed cases had proctitis
[20], in France only rectal swabs were included in the
surveillance system [47], and 91% of cases in Nether-
lands had proctitis [49]. Similarly only aggregate infor-
mation was available for LGV genotype, but Canada
[12], France [47] and the Netherlands [46] found only
L2b genotype in the samples that were sequenced.
Other descriptive studies selected for this study found
mainly L2 serotype with predominantly L2b variant in
the sequenced samples (such as 426/470 of samples in
UK surveillance that were confirmed L2b [20]). Primary
data sources would be needed to analyse differences
between HIV positive and HIV negative LGV cases.
A number of detailed reviews have been published on
the emergence of LGV [14,51]. However to our knowl-
edge this review is the first to systematically identify and
quantitatively analyse the association between HIV and
LGV in the re-emergence of LGV, and includes data
from 17 reports. However, it is limited by the inclusion
of a number of surveillance reports. Surveillance of LGV
is said to suffer from the lack of consistency between
countries giving rise to different case-definitions and
surveillance methods, some of which are based on
voluntary and potentially partial reporting [52]. Surveil-
lance reports formed a large proportion of publications
used for the HIV-prevalence estimates, but the studies
in this review all defined detection of LGV serovars as a
requirement for confirmed cases. Nevertheless it is pos-
sible that cases have been identified with different accu-
racy between countries and the international data may
not be comparable. Previous literature has noted that
the variation in the structure of surveillance systems
limits cross-country comparison [53]. The geographical
differences may be a result of variation in sexual part-
nerships, differential sexual behaviours (such as seroa-
daptive behaviour), testing and case finding policies,
time of introduction of LGV into the network and the
impact of local public health interventions [50].
In this review we did not apply strict quality criteria.
This is due to the relatively small number of published
studies and our desire to be inclusive in order to
increase sample size. This means that we cannot exclude
the possibility that sampling and measurement differ-
ences may account for some of the heterogeneity. Out-
come-level assessment for LGV was performed by
including only confirmed cases (identification of LGV
serovars required for a confirmed case) which assures
the validity of the data for the main outcome. Due to
the small number of studies conducted to date and the
recent emergence of LGV, publication bias was not
thought to be relevant in this analysis. The search and
article retrieval was conducted by the first author alone,
Figure 2 Forest plot of HIV-LGV association using fixed-effect
model.
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but the analysis and interpretation was done by both
authors.
The strong association between LGV and HIV in an
unadjusted model is interesting, and some association
would be expected to remain after adjusting for confoun-
ders, especially since the association is strong even though
the control group represents another high risk group of
MSM with a non-LGV CT infection. It is possible that
there may be a biological interaction between HIV-infec-
tion and LGV. HIV-infection has been reported to cause
abnormalities in the structure and function of the gastro-
intestinal tract as well as abnormal lymphocyte trafficking
[54] that may facilitate LGV acquisition. In a South Afri-
can cohort of patients with GUD, LGV infection was diag-
nosed more often among the HIV-infected participants
compared to HIV-negative participants with relative risk
1.3 (95% CI 1.2-1.4) [55]. Also in the Bahamas, an LGV
epidemic was associated with crack cocaine use and HIV
infection [56]. Two of the case-control studies included in
this review compared median CD4 count between cases
and controls, but neither found a significant difference
[57,58]. van der Bij et al. [18] also hypothesised that
immunorestoration inflammatory syndrome could explain
the emergence of this highly symptomatic LGV. They ana-
lysed the association between having symptomatic LGV
and start of highly active antiretroviral therapy (HAART)
but no association was found. Time-series analysis may be
a more effective way to measure the potential interaction
between HIV and LGV.
The strongest confounder for this hypothesis is high-
risk sexual behaviour. There have been behavioural
changes in MSM communities as a response to HIV
epidemic, and serosorting may make HIV-positivity an
intermediating factor: individuals participate in certain
type of practices partly because of their HIV-infection
[59]. Seroadaptive behaviour can reduce the number of
new HIV infections but it also facilitates the spread of
other STIs and can create dense sexual networks where
disease propagation is fast [53]. Exploring this further
was not possible in this review because of the lack of
comparable data on sexual behaviour.
Conclusions
The findings from HIV prevalence estimates and case-
control studies reveal that HIV-infected MSM are dis-
proportionately affected by the emergence of LGV. LGV
prevention efforts should be targeted towards HIV-
infected sexually active MSM. Although the majority of
LGV infected individuals are HIV-positive, a proportion
of diagnosed LGV cases are HIV-negative and this
group would benefit from primary HIV prevention as
they belong to sexual networks where HIV-seropositivity
is common and subsequently they are at high risk of
HIV-infection.
The strong association between LGV and HIV co-
infection identified from case control studies may indi-
cate a biological synergy between LGV and HIV, but
further research is required to explore the relationship
between HIV-infection, behaviour and acquisition of
LGV.
Additional material
Additional file 1: Table S1 and Table S2. Table S1 presents the
descriptive studies selected for the analysis of prevalence of HIV co-
infection in LGV cases, and Table S2 presents the case-control studies
with estimates of association between HIV-positivity and LGV [60-67].
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